Abstract: The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: An arrangement for operation to reduce organic contaminant concentration in water passing therethrough as provided. The arrangement includes at least one reactor comprising a plurality of treatment chambers oriented in series, each chamber including an upstream downcomer portion and a downstream column portion separated by a wall member. Fluid flow is provided between a downcomer portion and the column portion. Means are provided such that water can flow through any associated chamber by introduction into an upper portion of the downcomer portion of the chamber, with passage downwardly to a feed space and a bottom portion of the column portion of the chamber and upwardly through the column portion. The water then flows outwardly from the chamber, into a next downstream chamber if one is provided.

Abstract: An arrangement for operation to reduce organic contaminant concentration in water passing therethrough as provided. The arrangement includes at least one reactor comprising a plurality of treatment chambers oriented in series, each chamber including an upstream downcomer portion and a downstream column portion separated by a wall member. Fluid flow is provided between a downcomer portion and the column portion. Means are provided such that water can flow through any associated chamber by introduction into an upper portion of the downcomer portion of the chamber, with passage downwardly to a feed space and a bottom portion of the column portion of the chamber and upwardly through the column portion. The water then flows outwardly from the chamber, into a next downstream chamber if one is provided.